Taletrectinib, a next-generation TKI, is approved for ROS1-positive NSCLC, showing high ORR and durable responses in clinical trials. TRUST-I and TRUST-II trials demonstrated efficacy in both ...
Taletrectinib's NDA is based on phase 2 TRUST-I and TRUST-II trials, showing significant efficacy in ROS1-positive NSCLC. The trials reported tumor shrinkage in 89% of TKI-naive and 56% of ...
Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The ...
Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, ...
The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback